Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Debt (2024 - 2025)

Historic Non-Current Debt for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $5.3 million.

  • Kura Oncology's Non-Current Debt fell 3121.05% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 3121.05%. This contributed to the annual value of $6.9 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Kura Oncology reported Non-Current Debt of $5.3 million as of Q3 2025, which was down 3121.05% from $6.5 million recorded in Q2 2025.
  • Kura Oncology's Non-Current Debt's 5-year high stood at $9.4 million during Q1 2024, with a 5-year trough of $5.3 million in Q3 2025.